Chen Gaowen, Zhu Lin, Yang Yulu, Long Yusheng, Li Xiangyuan, Wang Yifeng
1 Department of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
2 Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818791500. doi: 10.1177/1533033818791500.
The aim of the study was to investigate the prognostic role of neutrophil to lymphocyte ratio in ovarian cancer. Growing number of articles reported the relationship between neutrophil to lymphocyte ratio and prognosis in ovarian cancer, but the results remains inconclusive. The meta-analysis was conducted to analyze the association of pretreatment neutrophil to lymphocyte ratio with overall survival and progression-free survival.
We performed a systematic literature research of PubMed, EMBASE, Medline, and Cochrane library for relevant studies up to October 8, 2017. The quality of included studies was assessed by the Newcastle-Ottawa Quality Assessment Scale. The hazard ratio and corresponding 95% confidence intervals were calculated. We checked the heterogeneity by the Q test and Higgins I-squared statistic. Begg funnel plot and Egger linear regression test were also applied for ascertain publication bias. All of the statistical analyses were performed using STATA version 12.0.
A total of 12 studies with 4046 patients were included in our study. The results indicated that depressed neutrophil to lymphocyte ratio was significantly correlated with higher overall survival (hazard ratio = 1.409, 95% confidence intervals = 1.112-1.786, P = .005) and progression-free survival (hazard ratio = 1.523, 95% confidence intervals = 1.187-1.955, P = .001) in ovarian cancer. Subgroup analysis by ethnicity of overall survival and progression-free survival showed that the prognostic effect of neutrophil to lymphocyte ratio was found both in Asians and Caucasians.
Patients with depressed neutrophil to lymphocyte ratio had a higher overall survival and progression-free survival in ovarian cancer. This meta-analysis provided neutrophil to lymphocyte ratio as an available predictor of overall survival and progression-free survival for patients with ovarian cancer.
本研究旨在探讨中性粒细胞与淋巴细胞比值在卵巢癌中的预后作用。越来越多的文章报道了中性粒细胞与淋巴细胞比值与卵巢癌预后之间的关系，但结果仍无定论。本荟萃分析旨在分析治疗前中性粒细胞与淋巴细胞比值与总生存期和无进展生存期的关联。
我们对PubMed、EMBASE、Medline和Cochrane图书馆进行了系统的文献检索，以查找截至2017年10月8日的相关研究。纳入研究的质量通过纽卡斯尔-渥太华质量评估量表进行评估。计算风险比及相应的95%置信区间。我们通过Q检验和Higgins I²统计量检查异质性。还应用Begg漏斗图和Egger线性回归检验来确定发表偏倚。所有统计分析均使用STATA 12.0版本进行。
我们的研究共纳入了12项研究，涉及4046例患者。结果表明，在卵巢癌中，较低的中性粒细胞与淋巴细胞比值与较高的总生存期（风险比=1.409，95%置信区间=1.112-1.786，P=.005）和无进展生存期（风险比=1.523，95%置信区间=1.187-1.955，P=.001）显著相关。按总生存期和无进展生存期的种族进行亚组分析表明，在亚洲人和白种人中均发现了中性粒细胞与淋巴细胞比值的预后作用。
中性粒细胞与淋巴细胞比值较低的卵巢癌患者具有较高的总生存期和无进展生存期。本荟萃分析提供了中性粒细胞与淋巴细胞比值作为卵巢癌患者总生存期和无进展生存期的一个可用预测指标。
